Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31368108 | 0.98 | OPRM1 (0.50) | OPRM1SMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL20601546 | 0.89 | OPRM1 (0.52) | OPRM1SMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL31117190 | 0.85 | ALDH1A1 (0.53) | OPRM1SMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL4944766 | 0.85 | ALDH1A1 (0.57) | OPRM1SMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL10112796 | 0.84 | OPRM1 (0.51) | OPRM1 | |
| SCHEMBL653528 | 0.84 | DRD2 (0.51) | OPRM1SMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL21726313 | 0.84 | ALDH1A1 (0.56) | OPRM1SMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL378799 | 0.84 | OPRM1 (0.70) | OPRM1MEN1KMT2A | |
| SCHEMBL378824 | 0.84 | OPRM1 (0.74) | OPRM1 | |
| Hydrochloric Acid SCHEMBL23535437 | 0.83 | OPRM1 (0.50) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250092036-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-03-20 | — | — | US | disclosed |
| WO-2025037229-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | NOVARTIS AG (CH) | 2025-02-20 | — | — | WO | disclosed |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024254532-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092036-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | MAPK1, MAP3K1, MAPK6 | OPRM1 2763/4885SMN1; SMN2 3024/4885MAPT 1311/4885 |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | SMARCA2, SMARCE1, SMARCB1 | OPRM1 4448/4885SMN1; SMN2 497/4885MAPT 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.